超捷股份(301005.SZ):公司商業航天火箭箭體結構件鉚接產線於2024年5月建成並投產
格隆匯7月17日丨有投資者通過互動平台向超捷股份(301005.SZ)提問:貴公司回覆,商業航天業務領域廣闊,公司已設立專門商業航天業務團隊,目前業務主要為商業火箭箭體結構件製造,包括殼段、整流罩、發動機閥門等,在今年5月已完成產線建設。請問該產線設計產能是多少?是否滿足相關訂單產能,謝謝
超捷股份(301005.SZ)回覆:公司商業航天火箭箭體結構件鉚接產線於2024年5月建成並投產,可生產包括殼段、整流罩、發動機閥門等產品,設計產能年產10發,公司會根據客户訂單調整產線產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.